Superworth

Nexentis Technologies EPS NXTS

Diluted earnings per share by quarter and over the last twelve months, from 2019.

Last 12 months, to Jun 30, 2026
n/m
a quarter missing
Latest quarter, Q2 FY26
−$13.66
Fiscal year 2024
−$245.00

Nexentis Technologies' twelve-month earnings per share can't be added up yet: a quarter of its results is missing from our data.

In its latest quarter, Q2 FY26, it was −$13.66.

Earnings per share over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearEPSChange
FY2024−$245.00n/a
FY2023−$1452.85n/a
FY2022n/an/a
FY2021−$3464.30n/a
FY2020−$1835.05n/a
FY2019−$2349.55n/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedEPSOn a year earlierLast 12 months
Q2 FY26−$13.66n/an/a
Q1 FY26−$10.74n/an/a
Q3 FY25$6.79n/a−$152.12
Q2 FY25−$44.26n/a−$254.46
Q1 FY25−$85.25n/a−$266.55
Q4 FY24−$29.40n/a−$245.00
Q3 FY24−$95.55n/a−$460.60
Q2 FY24−$56.35n/a−$801.15
Q1 FY24−$63.70n/a−$913.85
Q4 FY23−$245.00n/a−$1452.85
Q3 FY23−$436.10n/a−$1707.65
Q2 FY23−$169.05n/a−$2043.30

Against its peers

Companies in Drug Manufacturers - General nearest Nexentis Technologies' size, closest first, today.

CompanyEPS, 12 months
NXTSNexentis Technologiesn/m
LABTLakewood-Amedex Biotherapeuticsn/m
JAGXJaguar Health−$6051.75
VBIOValion Bion/m
DCOYDecoy Therapeuticsn/m
SBFMSunshine Biopharman/m
ARTLArtelo Biosciences−$207.09
LNAILunai Bioworksn/m
GNPXGenprexn/m
GOVXGeoVax Labsn/m
ONCOOnconetix−$199.38
Peer median−$207.09

What the EPS figure tells you

Net income divided by diluted shares. The denominator of PE.

One-off charges and gains swing it. The TTM view smooths a single odd quarter.

More on Nexentis Technologies

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.